Point-of-care Diagnostics Market to be Worth $43.1 Billion by 2030

Traditional antibodies in lateral flow assays can be replaced with DNA nanostructures capable of binding with a target antigen with high binding affinity and specificity. For example, Atom Bioworks Inc. (U.S.) has developed the DNA Star PoC Diagnostics Platform, a lateral flow assay kit that contains nanoengineered DNA nanostructures instead of traditional antibodies. In 2021, the company was awarded the Rapid Testing Innovation Award at the Advanced Lateral Flow Conference organized by DCN Diagnostics (U.S.) and DIALUNOX GmbH (Germany).